Faecal calprotectin in the assessment of Crohn's disease activity

QJM: An International Journal of Medicine

Volumn 98, Issue 6, 2005, Pages 435-441

  Gaya, Daniel R ^a   Lyon, T D B ^a   Duncan, A ^a   Neilly, J B ^a   Han, S ^a   Howell, J ^a   Liddell, C ^a   Stanley, A J ^a   Morris, A J ^a   Mackenzie, J F ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALPROTECTIN;

ADULT; ARTICLE; CELL LABELING; CLINICAL ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; FECES ANALYSIS; FECES LEVEL; FEMALE; HUMAN; INFLAMMATION; ISOTOPE LABELING; LEUKOCYTE; MALE; PREDICTION; PRIORITY JOURNAL; RELAPSE; RELIABILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 20444421828     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hci069     Document Type: Article

References (43)

1. Armitage E, Drummond H, Ghosh S, Ferguson A. Incidence of juvenile-onset Crohn's disease in Scotland. Lancet 1999; 353:1496-7.
2. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three fold rise in Crohn's disease. Gut 1989; 30:618-22.
3. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo controlled, dose-ranging study. Gastroenterology 1996; 110:45-51.
4. Rutgeerts PJ. Prevention of early recurrence of Crohn's disease after ileal resection with ileocolic anastomosis. Eur J Gastroenterol Hepatol 1994; 6:113-16.
5. Holmquist L, Ahren C, Fallstrom SP. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. A study in children and adolescents with chronic inflammatory bowel disease. Acta Paediatr Scand 1990; 79:327-34.
6. Fagerhol MK, Dale I, Anderson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of cells. Bull Eur Physiopathol Respir 1980; 16:273-82.
7. Steinbakk M, Naess-Andresen CF, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990; 336:763-5.
8. Sohnle PG, Collins-Lech C, Weissner JH. Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J Infect Dis 1991; 163:187-92.
9. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in faeces. A methodologic study. Scand J Gastroenterol 1992; 27:793-8.
10. Bunn SK, Bisset WM, Golden B. Faecal calprotectin - an objective measure of bowel inflammation in childhood inflammatory bowel disease. J Paediatr Gastroenterol Nut 2001; 32:171-7.
11. Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993; 28:1073-6.
12. Melling TR, Aabakken L, Roseth AG, et al. Faecal calprotectin shedding after short term treatment with non-steroidal anti-inflammatory drugs (NSAIDs). Scand J Gastroenterol 1996; 31:339-44.
13. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45:362-6.
14. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index; National Cooperative Crohn's Disease study. Gastroenterology 1976; 70:439-44.
15. Hodgson HJF. Assessment of drug therapy in inflammatory bowel disease. J Clin Pharmacol 1982; 14:159-70.
16. De Dombal FT, Softley A. I0IBD report no. 1: observor variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987; 28:474-81.
17. Beck IT. Laboratory assessment of inflammatory bowel disease. Dig Dis Sci 1987; 32:265-315.
18. 99mTc white blood cells. Radiology 1999; 212:507-13.
19. Peters AM, Danpure HS, Osman S, et al. Clinical experience with technetium-99m hexamthyl propylene amine oxine for labelling leucocytes and imaging inflammation. Lancet 1986; 2:946-9.
20. Lanatto E, Jarvi K, Krekela I, et al. Technetium-99m hexamthyl propylene amine oxine leucocytes in the assessment of disease activity in inflammatory bowel disease. Eur J Nuc Med 1992; 19:14-18.
21. Papos M, Nagy F, Lang J, et al. Technetium-99m hexamthyl propylene amine oxime labelled leucocyte scintigraphy in ulcerative colitis and Crohn's disease. Eur J Nuc Med 1993; 20:766-9.
22. Poullis A, Irwin AG, Dearing M, et al. Methodological study to assess repeat planar white cell scanning in monitoring the efficacy of treatment of inflammatory bowel disease. Gut 2003; 52(S1):A87.
23. Saverymuttu SH. Clinical remission in Crohn's disease - Assessment using faecal indium-111 granulocyte excretion. Digestion 1986; 33:74-9.
24. Bunn SK, Bisset WM, Main MJ, et al. Faecal calprotectin: validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. J Paediatr Gastroenterol Nut 2001; 33:14-22.
25. Fireman Z, Mahajna E, Broide E, et al. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut 2003; 52:390-2.
26. Holmquist L, Ahren C, Fallstrom SP. Clinical disease activity and inflammatory activity in the rectum in relation mucosal inflammation assessed by colonoscopy. A study of children and adolescents with chronic inflammatory bowel disease. Acta Paediatr Scand 1990; 79:527-34.
27. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease study. Gastroenterology 1976; 77:829-42.
28. Andre C, Descos L, Landias P, et al. Assessment of approximate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22:571-4.
29. Saverymatta SH. Clinical remission in Crohn's disease assessment using faecal 111In granulocyte excretion. Digestion 1986; 33:74-9.
30. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Gastroenterology 1990; 98:811-18.
31. Tibble JA, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47:506-13.
32. Teahon K, Smethurst P, MacPherson AJ, et al. Intestinal permeability in Crohn's disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol Hepatol 1993; 5:79-84.
33. Saverymuttu SH, Peters AM, Lavender JP, et al. Quantitative faecal indium-111 labelled leucocyte excretion in assessment of disease activity in Crohn's disease. Gastroenterology 1983; 85:1333-9.
34. Scholmerich J, Schmidt E, Schumichen C, et al. Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium-99m hexamthyl propylene amine oxine as a leukocyte label. Gastroenterology 1988; 95:1287-93.
35. Jobling JC, Lindley KJ, Yousef Y, et al. Investigating inflammatory bowel disease: white cell scanning, radiology and colonoscopy. Arch Dis Child 1996; 74:22-6.
36. Vilien M, Nielsen SL, Jorgensen M, et al. Leucocyte scintigraphy to localise inflammatory activity in ulcerative colitis and Crohn's diease. Scand J Gastroenterol 1992; 27:582-6.
37. Gibson P, Liechtentein M, Sclechi N, et al. Value of positive technetium 99m leucocyte scanning in predicting intestinal inflammation. Gut 1991; 32:1502-7.
38. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocytic protein calprotectin. Mol Pathol 1997; 50:113-23.
39. Yiu S, Mikami M, Yamazaki M. Induction of apoptoic cell death in mouse lymphoma and human leukaemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukoc Biol 1995; 336:763-5.
40. Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 2003; 35:607-9.
41. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58:176-80.
42. Becker W, Fischbach W, Weppler M, et al. Radiolabelled granulocytes in inflammatory bowel disease: diagnostic possibilities and clinical indications. Nucl Med Common 1988; 9:698-701.
43. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34:50-4.